








Establishment of a spontaneously
transformed cell line (JU-PI) from a
myxoinflammatory fibroblastic
sarcoma
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Abstract
Myxoinflammatory fibroblastic sarcoma is a soft-tissue neoplasm most frequently found in the distal extremities of
middle-aged adults. Most myxoinflammatory fibroblastic sarcoma are low-grade tumors with propensity for local recur-
rence after incomplete removal. We report a myxoinflammatory fibroblastic sarcoma which developed in the foot of a
41-year-old male and showed an exceptionally aggressive course with metastatic spread and fatal outcome within
16 months. We managed to establish a spontaneously transformed continuous cell line, called JU-PI, from a metastatic
lesion. The JU-PI cells have a sub-tetraploid karyotype including the 1;10 chromosomal translocation and amplification of
the proximal end of 3p; these features are considered genetic signatures of myxoinflammatory fibroblastic sarcoma.
Both the primary tumor and the JU-PI cells showed nuclear expression of the TFE3 transcription factor but TFE3-acti-
vating chromosomal rearrangements were not found. To our knowledge, JU-PI is the first established myxoinflammatory
fibroblastic sarcoma cell line. JU-PI cells offer a tool for investigating the molecular oncology of myxoinflammatory fibro-
blastic sarcoma.
Keywords
Sarcoma cell line, myxoinflammatory fibroblastic sarcoma, TFE3, 3p11-3p12.1 amplification
Date received: 08 November 2017; accepted: 22 April 2018
Introduction
Myxoinflammatory fibroblastic sarcoma (MIFS) is a
rare soft-tissue neoplasm that was described as a sepa-
rate entity 20 years ago. MIFS most frequently arises as
a painless slow-growing tumor in the distal extremities
of adults in their 40s with no obvious gender predomi-
nance.1–3 The histology of MIFS may be pleomorphic,
which makes initial diagnostics challenging. The tumor
consists of spindle cells and epithelioid cells with abun-
dant cytoplasm. Other tumor cells may have a vacuo-
lated cytoplasm described as pseudolipoblasts. Also
cells with large bizarre nuclei resembling Reed-
Sternberg/Hodgkin’s cells are frequently found.1,4–6A
common feature is the presence of areas of myxoid
changes and infiltration of inflammatory cells including
lymphocytes, plasma cells, and macrophages in the
tumor tissue.1
MIFS is generally considered a neoplasm of low malig-
nancy with propensity for local recurrence after incomplete
removal.1,4 High-grade, metastasizing forms of MIFS are
rare, reported to represent some 2% of the cases.3
Cytogenetic studies on MIFS have revealed a typical
reciprocal translocation between chromosomes 1 and
1Department of Pathology, University of Helsinki, Helsinki, Finland
2HUSLAB and Helsinki University Hospital, Helsinki, Finland
Corresponding author:
Leif C Andersson, Department of Pathology, University of Helsinki, PO
Box 21 (Haartmaninkatu 3) 00014 Helsinki, Finland.
Email: Leif.Andersson@helsinki.fi
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial
use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and
Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
10 t (1:10) (p22; q24), leading to juxtapositioning of
parts of the TGFBR3 and MGEEA5 genes.7,8 No
fusion product is formed, however, since the genes are
transcribed in opposite directions. The translocation
leads to secondary activation of the FGF8 gene that
displays elevated expression in MIFS as in various neo-
plasms including synovial sarcoma and cancer of the
breast and prostate.9,10 Another cytogenetic feature is
amplification of the segment 3p11-3p12 leading to
overexpression of the VGLL3 and CHMP2B genes.4
Amplification of VGLL3 is a frequent finding in differ-
ent high-grade sarcomas.11
No definite risk factors for MIFS have been identi-
fied. A role for repeated trauma has been suggested.12
The presence of large ‘‘virocyte’’-like tumor cells may
indicate an infectious etiology, but consistent evidence
for viral signatures has not been found.1,13
Immortalized tumor cell lines offer tools for investi-
gating the molecular biology of neoplasms. In this
study, we describe the establishment and initial charac-
terization of a spontaneously transformed continuous
cell line, JU-PI from a metastatic MIFS. To the best of




A 41-year-old male came for surgical removal of a
swelling on the dorsum of his foot. The first histo-
pathological diagnosis was villonodular synovitis, a fre-
quently encountered initial misdiagnosis of MIFS.
Recurrence occurred within 6months of the first meet-
ing. IVADIC (Ifosfamide, vincristine, doxorubicin,
dacarbazin)14 treatment was started during which the
illness showed progression. Ten months after the initial
surgery, a metastatic tumor was removed from the
inguinal region. One month later, the patient returned
with metastatic lesions in the foot. Radiation therapy
was initiated but the response was poor. Palliative
amputation of the leg was performed after 1month.
New tumor growth occurred in the scar tissue. A
whole-body CT scan revealed a widespread disease
with metastases in both lungs and in the retroperito-
neum. No response to treatment with etoposide was
obtained and the patient succumbed to the tumor
16months after the first intervention.
Tissue handling
Tissue samples were fixed in 10% phosphate buffered
formalin and embedded in paraffin blocks for histology
and immunohistochemistry. Fresh tissue was recovered
from the recurrent tumor and the metastatic lesions,
and was used for extraction of DNA and for in vitro
culturing.
Immunohistochemistry
Immunohistochemistry on sections from formalin-fixed
and paraffin embedded material was performed using a
Ventana Benchmark XT automated stainer (Ventana
Medical Systems, Inc., USA). The primary antibodies
employed are listed in Table 1. Cells were cultivated on
object glasses (SuperFrost Ultra Plus, Menzel
GmbH & Co KG, Saarbrückener Str. 248, D-38116
Braunschweig), and fixed for 30min in 10% formalin
for immunocytochemistry.
Establishment of a cell line
Fresh metastatic tumor tissue recovered from the groin
was minced with a scalpel. The tissue fragments were
treated with collagenase (2mg/mL, Type IV, Sigma)
and DNA:se (100mg/mL, Sigma) in serum-free culture
medium for 4 h at 37C under agitation. The cell sus-
pension was pelleted by centrifugation, washed once
Table 1. Antibodies used for immunohistochemistry.
Antigen Clone Dilution Manufacturer
Vimentin V9 1:500 Dako, M0725
CAm5.2 CAM5.2 1:50:00 BD, 345779
S-100 Polyclonal 1:700 Dako, Z0311
HMB-45 HMB45 1:100 Dako, M0634
Smooth muscle actin 1A4 1:100 Dako, M0851
CD3 PS1 1:100 Novocastra, NCL-cd3-PS1
CD20 L26 1:1000 Dako, M0755
CD31 JC70A 1:25 Dako, M0823
CD34 My10+8G12 1:50 BD, 347660
CD56 504 1:50 Novocastra, NCL-CD56-504
CD68 KP1 1:400 Dako, M0814
Ki-67 MIB-1 1:75 Dako, A0047
TFE3 MRQ-37 RTU Roche/Ventana, 760-4622
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with RPMI-1640 culture medium, plated in RMPI-1640
culture medium supplemented with 10% fetal bovine
serum and antibiotics (Penicillin and Streptomycin) and
cultured at 37C in a humidified atmosphere of 5%
CO2 in air. Focal outgrowth of adherent, spindle-
shaped cells was seen within 1week of primary cultur-
ing. After an initial phase of slow growth for about
1month, a more rapidly proliferating monomorphic
population of spindle shaped cells emerged. The cul-
tures were divided twice weekly after detachment of the
cells by treatment with Trypsin-Versene ( 2009 Lonza
Walkersville, Inc.). We called the established cell line
JU-PI. The cell line (passage 9) was cryopreserved from
2001 until 2016 when this study was initiated.
Isolation of DNA
DNA was isolated using a proteinase K-based method
according to the manufacturer’s instructions (Thermo
Fisher Scientific Baltics UAB, V.A. Graiciuno 8, LT-
02241 Vilnius, Lithuania). The isolated JU-PI DNA
was from a passage 36.
Microsatellite analysis
Microsatellite analysis of DNA isolated from fresh frozen
tumor tissue and JU-PI cells (passage 36) was performed
by polymerase chain reaction (PCR) amplification of 11
microsatellite loci using fluorescently labeled primers.
The PCR products were separated by capillary electro-
phoresis (3130XL Genetic Analyzer, Applied Biosystems)
and analyzed by using GeneMapper 5 software.
Comparative genomic hybridization
Comparative genomic hybridization (CGH) with DNA
from fresh tumor tissue and JU-PI cells (passage 36)
was carried out using Cancer+SNP 4 3 180k micro-
array (Oxford Gene Technology, Oxford, UK).
Labelling, hybridization, scanning, and analysis were
done according to the manufacturer’s instruction. The
microarray slides were scanned using an Agilent DNA
Microarray Scanner G2505 (Agilent Technologien Inc,
Santa Clara, CA, USA) and filtered with Feature
Extraction software v12.0.07 (Agilent Technologies).
The Cytosure Software v4.9 (Gh19) (Oxford Gene
Technology) was used for graphic analysis of the data.
Karyotype and multicolor FISH
Cell culturing and metaphase-fluorescence in situ hybridi-
zation (FISH) preparations were done according to stan-
dard cytogenetic procedure.15 Twenty-four color FISH
karyotyping was performed with 24XCYte mFISH probe
kit (MetaSystems GmbH, Altslussheim, Germany).
Hybridizations and post-hybridization washes were
performed according to the manufacturers’ instructions.
(A Zeiss Axioplan 2 Microscope equipped with specific fil-
ters was used.) Images were captured and processed using
the Isis/Multicolor FISH imaging system (MetaSystems).
Electron microscopy
Cells in culture were fixed by pre-warmed 2.5% glutaral-
dehyde in culture medium at 37C for 15min, scraped off
the plates and pelleted by centrifugation. The pellets were
further fixed in 2.5% glutaraldehyde for 1h. The fixed
sample was post-fixed by 1% osmium tetroxide, dehy-
drated in graded ethanol, embedded by Epoxy LX-112
resin. Sections of 60–80nm thickness were cut, observed
under a JEOL JEM1400 (Tokyo, Japan) at 80kV. Digital
electron micrographs were taken by a Morada TEM digi-
tal camera (EMSIS GmbH, Muenster, Germany).
Growth curve
The cell numbers in triplicate daily samples from paral-
lel JU-PI cultures were counted in a hemocytometer.
Results
Morphology of the primary and recurrent tumors
Myxoid and solid areas could be seen in both the primary
and metastatic tumors, with more abundant solid areas
in the metastases. Some slit-like spaces without any lining
cells as well as necrotic areas were found. The tumor cells
were epithelioid or spindle shaped with large nucleoli,
and their mitotic activity was high. Atypical mitotic fig-
ures were observed in both the primary and metastatic
tumors. Occasional multinucleated giant cells with atypi-
cal nuclei were seen (Figure 1(a) and (b)). Inflammatory
cells accumulated mostly around necrotic areas but also
lining fibrotic streaks in the tumor. In some of the tumor
cells, intracytoplasmic accumulation of period acid-Schiff
(PAS) material was observed (Figure 1(c) and (d)).
Immunohistochemistry
Immunohistochemistry performed on sections from both
the primary and metastatic tumors showed positivity for
vimentin and TFE3. The TFE3 staining was nuclear in
the tumor cells (Figure 1(e) and (f)).The proliferation
index measured by Ki-67 was 10% in the primary tumor
and over four times higher in the metastases (Figure 1(g)
and (h)). The other antibodies listed in Table 1 yielded
no positive staining of the tumor cells.
Genetics of the tumor
CGHs were performed using tumor-derived DNA in
2000–2001. The main findings were loss of chromosome
Fagerstedt et al. 3
13 and amplification of p12.3 close to the centromere
on chromosome 3.
Growth pattern of JU-PI cells
After plating, spindle-shaped JU-PI cells grew in adher-
ent monolayers. Before reaching confluence, the cells
piled up in loose, organoid-like aggregates. Most cells
contained a single nucleus with one or several more
prominent nucleoli. Accumulation of intracytoplasmic
light-refracting granules of 0.5–1mm was seen after
extended cultivation, particularly in cells forming
adherent aggregates (Figure 2(a)). Phase contrast
microscopy revealed an abundance of slender thread-
Figure 1. Histology and IHC of the primary tumor (a, c, e, g) and of the metastatic tumor (b, d, f, h). PAS-positive material in the
tumor cells (c, d). Nuclear localization of TFE expression (e, f) and of Ki-67 expression (g, h).
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like protrusions on the cell surface membranes (Figure
2(b)).
Growth curve
The growth curve revealed proliferation for 4 days after
which a plateau was reached. The doubling time was
calculated to be 1.1 days (Figure 3).
Staining of the JU-PI cells
The staining of JU-PI cells cultivated on object
glasses showed intracytoplasmic accumulation of
PAS-positive material in many cells (Figure 2(c)).
Immunocytochemistry revealed nuclear positivity for
TFE3 (Figure 2(d)).
Figure 2. Morphology and immunocytochemistry of JU-PI cells. Phase-contrast pictures of growing cells (1003) (a) and at higher
magnification (4003) (b) showing intracyoplasmic light-refracting material and slender membrane protusions. Intracytoplasmic PAS-
positive material (c) and nuclear expression of TFE3 (d). TEM pictures of JU-PI cells (e, f).
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TEM
TEM images showed abundant 10 nm intermediate fila-
ments organized in a random fashion. Aggregation of
filaments to fibrils of 30–40 nm in diameter was also
seen. Some fibrils appeared densely packed in one pole
displacing the organelles to the other side of the cell.
The filaments were not arranged in crystal-like aggre-
gates like those described in alveolar soft part sarcoma.
In some cells, the RER was found to contain proteinac-
eous masses. An abundance of dendrite-like projections
on the cell surface membrane was also evident. No
intercellular junctions were formed even when the cells
were closely positioned with juxtaposed cell membranes
(Figure 2(e) and (f)).
Genetics of the cell line
The results of the chromosome painting (M-FISH)
done on JU-PI revealed a nearly tetraploid chaotic kar-
yotype with chromosome numbers ranging between 81
and 97. A consistent finding was the loss of chromo-
somes 13 and Y (Figure 4c).
The most frequently found translocations were
t(1;5), t(1;10), t(7;13), t(1;15), and t(14;17). CGH, using
JU-PI cell DNA showed a prominent amplicon in the
chromosomal region 3p11-3p12.3 (Figure 4(b)). CGH
also confirmed the loss of genetic material of whole
chromosomes Y and 13. The findings on chromosomal
level are summarized in Figure 4(a). The lack of chro-
mosome 13 implies absence of the tumor suppressor
gene RB1. The loss of 17p13.1 containing the TP53
gene was also revealed by CGH. In addition, several
deletions or amplifications of chromosomal regions
containing genes of importance for neoplastic growth
were found. These are summarized in Table 2.
To confirm the derivation of the JU-PI cell line from
the original tumor, we performed a microsatellite anal-
ysis of 11 microsatellite loci. They showed identical
results in the tumor and the cell line, which demon-
strates that the cell line JU-PI originates from the
resected tumor material (data not shown). The findings
also confirmed the CGH results showing deletions of
genetic material from chromosome 13 and loss of the
whole Y chromosome.
Discussion
We report the establishment of a spontaneously trans-
formed continuous cell line from a metastatic lesion of
an exceptionally aggressive MIFS with early metastatic
spread and fatal outcome.
MIFS usually displays a benign clinical course.
Laskin et al.16 reported 104 cases of MIFS, and of 59
cases with accessible follow-up, only one presented with
metastatic disease. Michal et al.6 collected 23 cases of
high-grade MIFS out of which 9 developed a meta-
static disease which became fatal for 7 patients.
The primary tumor described here was initially (in
2000) diagnosed as proliferative villonodular synovitis.
Later biopsies from the metastases were diagnosed as
sarcoma NOS. Immunohistochemistry did not show
staining patterns of differential diagnostic value. After
establishment of the cell line, the morphology of the
primary tumor and the metastatic lesions were re-
evaluated and found to fulfill the histological criteria
described for MIFS. TEM also revealed ultrastructures
typical to sarcoma and divergent from TEM findings in
carcinoma.
The JU-PI cell line was considered established to be
already after 6weeks of culture. The growth pattern of
adherent spindle shaped cells is typical for mesenchymal
neoplasms. Piling up of cells in organoid-like aggregates
occurs before the culture reaches confluence. These cell
aggregates did not display invasive growth in semisolid
medium (Matrigel) (data no shown). Whether the JU-
PI cells are tumorigenic upon heterotransplantation
remains to be established. The accumulation of slightly
Figure 3. Growth curve of JU-PI cells.






1p21.1 AMY2A Gastric cancer
10q25.1-q26.3 NEURL1 Enhancement of apoptosis
15q11.2-q22.2 ? Aggressiveness of urothelial
cancer
17p13 p53 Many cancers
21q22 ? Uterine leiomyosarcoma




light-refracting cytoplasmic granules prompted us to
use TEM to investigate the JU-PI cells. The granular
material, however, did not appear as the rhomboid
crystals typically found in alveolar soft part sarcoma
but rather as proteinaceous aggregates without a clear
structure. The composition of these granules is a matter
for forthcoming investigations.
The primary tumor as well as the metastases showed
areas of diastase-resistant PAS-positive staining both in
the tumor cells and the stroma. Intracytoplasmic accu-
mulation of PAS-positive material was also seen in the
JU-PI cells. This most likely represents mucopolysac-
charides that are compatible with the myxoid changes
characteristic for MIFS. Additional biochemical studies
are nevertheless required to disclose the molecular
nature of the PAS-positive material.
We found nuclear expression of TFE3 both in the
primary tumor and in JU-PI cells. We did not find pre-
vious reports on the expression of TFE3 in high-grade
variants of MIFS which may be due to the relative rar-
ity of the tumor. TFE3 is a transcription factor involved
in SMAD2/3 nuclear signaling and TGF-b signaling
Figure 4. Summary of the CGH on all chromosomes showing loss of the Y chromosome and chromosome 13 (a). CGH profile
showing the prominent amplicon on chromosome 3 (3p11-3p12.2) (b). Multicolor FISH of JU-PI karyotype showing the t(1;10)
translocation (arrows) and lack of Y chromosome (c).
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pathways. Dysregulated TFE3 expression occurring
particularly via gene fusions has been found to display
oncogenic activity. TFE3 expression is considered to be
a marker for alveolar soft part sarcoma where its
expression results from a translocation (X:17) (p11:q25)
that gives rise to ASPSCR1-TFE3 fusion transcripts.
Additional fusion partners of TFE3 (PRCC, SFPQ,
NONO, CLTC, and YAP117–20) have been identified in
renal cell cancer and perivascular epithelioid cell tumors
(PEcomas).
Karyotype analysis was not done on the primary
tumor material. In the JU-PI cell line, we did not find
known TFE3-activating chromosomal rearrangements.
We also performed RT-PCR investigation on mRNA
isolated from JU-PI cells but could not find evidence
for expression of either type 1 or type 2 ASPSCR1-
TFE3 fusion transcripts (data not shown). Elevated
expression of TFE3 has been reported to occur in hepa-
tic angioleyomyoma also in the absence of known
genetic rearrangements. It remains to be investigated
whether genetic rearrangements in JU-PI cells are driv-
ing the TFE3 expression or whether it is caused by a
gene dose effect due to chromosome X polysomy.
A recurrent t(1;10) translocation that is a genetic sig-
nature of MIFS8 was found in the karyotypes of JU-PI
cells. The same chromosomal rearrangement occurs
also in hemosiderotic fibrolipomatous tumors. This has
triggered speculations about the interrelationship
between these two rare soft-tissue neoplasms. This
question was recently thoroughly addressed by Boland
and Folpe21 in a comprehensive review which came to
the conclusion that MIFS and hemosiderotic fibrolipo-
matous tumor apparently represent different entities.
CGH using DNA from the primary tumor and JU-
PI cells revealed amplification of the proximal end 3p
(3p11-3p12.3). This change, in addition to MIFS has
been observed in a variety of high-grade sarcomas. This
amplicon has been shown to induce overexpression of
the VGLL3 and CHMP2B genes. Elevated expression
levels of VGLL3, which acts as a cofactor of the TEAD
family of transcription factors have been found to sti-
mulate tumor cell migration and invasion.4
Despite the male origin of the tumor, the Y chromo-
some was missing from all the analyzed karyotype
spreads of JU-PI cells. Deletion of the Y chromosome
has been reported to occur in a variety of neoplasms
such as prostate cancer, pancreatic cancer, squamous
cell carcinoma of the head and neck, leukemia, hepato-
cellular carcinoma, malignant peripheral nerve sheet
tumor angiosarcoma, and Kaposi’s sarcoma.22–24
In summary, we describe a high-grade, rapidly fatal
case of MIFS from which we managed to establish a
spontaneously transformed cell line JU-PI. The JU-PI
cells offer a novel model for studying the molecular
tumor biology of MIFS and related soft-tissue
neoplasms. The JU-PI cell line is freely available for
interested investigators.
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